Strategy
Venture
Sector
Life science tools
Year invested
2019
Status
Active
Headquarters
Boston, MA
Board member
Julian Park
Website
tessellatebio.com
140
Labs using the platform
Why we invested
Tessellate Bio builds benchtop systems that let biology teams run thousands of assays a day without adding headcount.
CapWise led the Series A in 2019 and the Series B in 2022. Its platform is now used in 140 labs across North America and Europe.
2019
Series A, led by CapWise
2 rounds
Led by CapWise
140
Labs using the platform
2022
Series B
The partnership
Julian Park
Head of Portfolio Operations
·
New York
Board observer, 2019 to today
View profile →
“They understood the science and still asked about the unit economics in the first meeting.”
Grace Lin
CEO, Tessellate Bio
Building something similar?
Seed to Series B in software infrastructure, life science tools and industrial technology.A partner reads every pitch.